About Lineage Cell Therapeutics
Lineage Cell Therapeutics is a publicly listed company based in Carlsbad (United States) founded in 1990. Lineage Cell Therapeutics is focused on developing allogeneic cell therapies. It operates on a HealthTech model. Lineage Cell Therapeutics has raised $45.8 million across 22 funding rounds from investors including Juvenescence, State of California and HHS. The company has 77 employees. Lineage Cell Therapeutics has completed 4 acquisitions, including Asterias Biotherapeutics, Canadian Neighbor Pharmacy and Glycosan. Its chief executive, as recorded, is Brian Culley. Lineage Cell Therapeutics offers products and services including OpRegen and OPC1. Its focus areas include Biotechnology and Cell Therapy. Its legal entity is Lineage Cell Therapeutics, Inc. Its competitors include Revance Therapeutics, Dermavant and Sol-Gel Technologies; 3 of its 3 listed competitors have raised funding.
Company details
Lineage Cell Therapeutics is engaged in the development of novel allogeneic cell therapies targeting serious neurological and ophthalmic conditions. The company utilizes a proprietary cell-based technology platform for designing, manufacturing, and testing specialized human cells. These cells are intended to replace or support dysfunctional cells caused by degenerative diseases, aging, or traumatic injuries. Programs such as OpRegen for dry AMD and OPC1 for spinal cord injury are advanced internally or with strategic partners like Genentech to enhance therapeutic value and success probability in the healthcare sector.
- Headquarters Carlsbad, United States
- Employees 77
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website lineagecell.com
- Social LinkedIn X Facebook YouTube
- Legal Name Lineage Cell Therapeutics, Inc.
- Annual Revenue$14.56 M (USD)53.24as on Dec 31, 2025
- Net Profit-$63.53 M (USD)-241.41as on Dec 31, 2025
- EBITDA-$21.08 M (USD)-1.01as on Dec 31, 2025
- Total Equity Funding$45.8M (USD)
in 22 rounds
- InvestorsJuvenescence
& 3 more
- Employee Count77
- Investments & AcquisitionsAsterias Biotherapeutics
& 3 more
Products & Services of Lineage Cell Therapeutics
Lineage Cell Therapeutics offers a comprehensive portfolio of products and services, including OpRegen and OPC1.
Cell therapy developed for dry AMD treatment in patients.
Cell therapy designed for spinal cord injury recovery.
Apps and channels of Lineage Cell Therapeutics
its YouTube channel Lineage Cell Therapeutics has 330 subscribers and 18 videos.
Videos from Lineage Cell Therapeutics
The most watched videos on Lineage Cell Therapeutics's YouTube channel, Lineage Cell Therapeutics (330 subscribers). Click a video to play it here.
More on Lineage Cell Therapeutics.
Funding Insights of Lineage Cell Therapeutics
Lineage Cell Therapeutics has successfully raised a total of $45.8M across 22 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $45.8M
- Total Rounds 22
- First Round $3.5M
(May 2009)
- Investors Count 4
Latest 10 of 22 funding rounds of Lineage Cell Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | Grant | – | – | ||
| May 2023 | $50,000 | Grant | – | – | |
| Sep 2020 | $576,440 | Grant | – | – | |
| Aug 2020 | $24.6M | Post-IPO | – | – | |
| Aug 2019 | $670,621 | Grant | – | – | – |
| May 2019 | $2.52M | Grant | – | – | – |
| Jun 2018 | $743,345 | Grant | – | – | – |
| May 2018 | $1.93M | Grant | – | – | – |
| Apr 2018 | $385,923 | Grant | – | – | |
| Sep 2017 | $2.23M | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Lineage Cell Therapeutics
Lineage Cell Therapeutics has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include Juvenescence, State of California and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Access to government programs and development services is provided. | 1997 | ca.gov | United States | |
Business development in Israel is supported by a government organization. | 1965 | matimop.org.il | Jerusalem, Israel | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health | 2017 | juvlabs.com | Dublin, Ireland |
Investor details for Lineage Cell Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Lineage Cell Therapeutics
1 people are tracked at Lineage Cell Therapeutics (1 in leadership); the tracked headcount is 77.
| Name | Role | Group |
|---|---|---|
Brian Culley | CEO | Leadership |
Complete people profiles for Lineage Cell Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Lineage Cell Therapeutics
Lineage Cell Therapeutics is a publicly listed company on the AMEX with ticker symbol LCTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Apr 2014
- Listed onNYSEAMERICAN: LCTX
- Listed entityLineage Cell Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS53566P1093
- Share price$0.91 (-4.8% on the day) · 2026-10-13
- Market capitalisation$229.7M
- EPS (diluted, trailing year)$-0.18
- Volume (last session)1,784,674
Financials of Lineage Cell Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $14.6M | -$63.5M | -$21.1M |
| 2024 | $9.5M | -$18.6M | -$20.9M |
| 2023 | $8.9M | -$21.5M | -$24.0M |
| 2022 | $14.7M | -$26.3M | -$21.8M |
| 2021 | $3.9M | -$43.0M | -$48.8M |
Detailed financial statements for Lineage Cell Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lineage Cell Therapeutics
Lineage Cell Therapeutics has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Asterias Biotherapeutics, Canadian Neighbor Pharmacy and Glycosan.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of cell therapy programs to treat cancer and neurological diseases | asteriasbio.com | Fremont, United States | 2013 | Nov 2018 | •••• | |
Canadian Neighbor Pharmacy is engaged in online distribution of generic medications. | asteriasbiotherapeutics.com | Menlo Park, United States | 2012 | Nov 2018 | •••• | |
Bio-medical research services and genomic databases are provided by XenneX. | xennexinc.com | Cambridge, United States | 2003 | Apr 2012 | •••• | |
Biocompatible hydrogels mimicking extracellular matrix are developed for tissue engineering. | glycosan.com | Alameda, United States | 2006 | Feb 2011 | •••• |
Complete acquisition details for Lineage Cell Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Lineage Cell Therapeutics
8 dated milestones of Lineage Cell Therapeutics across 34 years, from founding to its latest funding, stage changes and deals.
- Founded Lineage Cell Therapeutics is founded.
- Funding First funding round of $3.5M.
- Acquisition Acquires Glycosan.
- Acquisition Acquires Xennex.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Asterias Biotherapeutics.
- Acquisition Acquires Canadian Neighbor Pharmacy.
- Funding Latest funding round, Grant,.
Competitors of Lineage Cell Therapeutics
Lineage Cell Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Revance Therapeutics, Dermavant and Sol-Gel Technologies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| dermavant.com | 2016 | Phoenix, United States | $160M | Small molecule therapeutics for inflammatory skin diseases are developed. | ||
| sol-gel.com | 1998 | United States | $9M | Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis. |
Detailed competitors of Lineage Cell Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Lineage Cell Therapeutics
The website of Lineage Cell Therapeutics (lineagecell.com) receives about 9.5K visits a month and ranks #2,352,150 among all websites worldwide, #3,216 in Biotechnology and Pharmaceuticals.
- Monthly visits9.5K
▲ 16.1% vs previous month
- Unique visitors3.8K
per month
- Global rank#2,352,150
among all websites
- Category rank#3,216
Health · Biotechnology and Pharmaceuticals
- Bounce rate35%
- Pages per visit2.3
- Average visit54 sec
- DevicesDesktop 34% · Mobile 66%
Top companies in Orthopedics
3 companies that operate in the same segment as Lineage Cell Therapeutics (Orthopedics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lineage Cell Therapeutics
Complete news archive for Lineage Cell Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lineage Cell Therapeutics
Lineage Cell Therapeutics was founded in 1990 and raised its 1st funding round 19 years after it was founded.
Lineage Cell Therapeutics is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
Brian Culley is the CEO of Lineage Cell Therapeutics, as recorded in our data.
Lineage Cell Therapeutics is a funded company, having raised a total of $45.8M across 22 funding rounds to date. The company's 1st funding round was a Grant of $2.23M, raised on May 2009.
Lineage Cell Therapeutics has 77 employees.
Annual revenue of Lineage Cell Therapeutics is $14.56M as on Dec 31, 2025.
Lineage Cell Therapeutics is engaged in the development of novel allogeneic cell therapies targeting serious neurological and ophthalmic conditions. The company utilizes a proprietary cell-based technology platform for designing, manufacturing, and testing specialized human cells. These cells are intended to replace or support dysfunctional cells caused by degenerative diseases, aging, or traumatic injuries. Programs such as OpRegen for dry AMD and OPC1 for spinal cord injury are advanced internally or with strategic partners like Genentech to enhance therapeutic value and success probability in the healthcare sector.
Lineage Cell Therapeutics's top competitors include Revance Therapeutics, Dermavant and Sol-Gel Technologies.
Lineage Cell Therapeutics offers OpRegen and OPC1.
Yes, Lineage Cell Therapeutics is publicly traded on AMEX under the ticker symbol LCTX.
Lineage Cell Therapeutics has made 4 acquisitions, including Asterias Biotherapeutics, Canadian Neighbor Pharmacy, and Glycosan.
Lineage Cell Therapeutics has 4 investors. Key investors include Juvenescence, State of California, HHS, and Israel Innovation Authority.